EU committee approves SPC waiver
GwenGoat / iStockphoto.com
Proposed amendments to the EU’s supplementary protection certificate (SPC) manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
European Federation of Pharmaceutical Industries and Associations, supplementary protection certificate, European Commission, manufacturing waiver, generic